Binnacle Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Binnacle Investments’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$912	Buy	+2	New	+$814	﹤0.01%	765

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Binnacle Investments's ALNY Position: Q3 2025 in Review

Binnacle Investments opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2025: 2 shares worth $912. The stake represents ﹤0.01% of the portfolio and ranks #765 among its holdings.

821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

Binnacle Investments held 2 shares of Alnylam Pharmaceuticals worth $912 as of Q3 2025.
Alnylam Pharmaceuticals was a new Binnacle Investments position in Q3 2025.
Alnylam Pharmaceuticals made up ﹤0.01% of Binnacle Investments's portfolio in Q3 2025, its #765 holding.
821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Binnacle Investments's 13F filing for Q3 2025, filed 14 Nov 2025.